Related references
Note: Only part of the references are listed.Tumor Cell-Derived Angiopoietin-like Protein ANGPTL2 Is a Critical Driver of Metastasis
Motoyoshi Endo et al.
CANCER RESEARCH (2012)
Pharmacokinetic evaluation of axitinib
Brian Patson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
John Fruehauf et al.
CLINICAL CANCER RESEARCH (2011)
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
Jochen Roessler et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M. Weis et al.
NATURE MEDICINE (2011)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice
Manuela Schmidinger et al.
CANCER INVESTIGATION (2010)
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment
Hidenori Ojima et al.
CANCER SCIENCE (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature
Murad Aljiffry et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment
Boris Blechacz et al.
HEPATOLOGY (2008)
Molecular targeted therapies in hepatocellular carcinoma
Josep M. Llovet et al.
HEPATOLOGY (2008)
Cholangiocarcinoma - Natural history, treatment, and strategies for surveillance in high-risk patients
Patrick Yachimski et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2008)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
D. Yoshikawa et al.
BRITISH JOURNAL OF CANCER (2008)
Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis
R. A. A. Mohammed et al.
BRITISH JOURNAL OF CANCER (2007)
CEACAM6 gene expression in intrahepatic cholangiocarcinoma
K. Ieta et al.
BRITISH JOURNAL OF CANCER (2006)
Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature
G. Des Guetz et al.
BRITISH JOURNAL OF CANCER (2006)
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial
JJ Knox et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy
AE Sirica
HEPATOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
The molecular pathogenesis of cholangiocarcinoma
EP Berthiaume et al.
SEMINARS IN LIVER DISEASE (2004)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Cholangiocarcinoma: Recent progress. Part 1: Epidemiology and etiology
K Okuda et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)
Tumor angiogenesis: past, present and the near future
RS Kerbel
CARCINOGENESIS (2000)
Share Paper
